The Trump-Vance administration took office on Jan. 20, 2025. The White House proceeded to dismantle the U.S. Agency for International Development, which funded LGBTQ and intersex rights organizations ...

The sizzle is the excitement about the hunt for the next big blockbuster, and the only one that anyone sees on the horizon is ...

The Trump administration will appeal a federal judge’s ruling that declared the rescission of $2.6 billion in federal funds from Harvard University was unconstitutional. U.S. District Judge Allison ...

Every 40 seconds, someone in the U.S. has a heart attack or stroke, and in most cases, it’s their first. 1 The good news? The risk for these devastating events can actually be significantly reduced by ...

We recently published 12 Fresh Stocks Jim Cramer Discussed Along With His Latest Thoughts On Quantum Computing. Amgen Inc. (NASDAQ:AMGN) is one of the stocks Jim Cramer recently discussed. Amgen Inc. ...

Amgen Chairman, President and CEO Bob Bradway joins 'Mad Money' host Jim Cramer to talk quarterly results, its recent drug trials, what is ahead for the company and more. Got a confidential news tip?

Amgen Chairman, President and CEO Bob Bradway joins 'Mad Money' host Jim Cramer to talk quarterly results, its recent drug trials, what is ahead for the company and more. “I will not allow Donald ...

But the administration indicated it might not be necessary, as Congress moved toward a deal to fund the government. By Tony Romm and Abbie VanSickle Reporting from Washington The Trump administration ...

The Trump administration has notified the U.S. Supreme Court that it still wants to fight a lower court ruling requiring full SNAP benefits be paid for November. The move comes after an appeals court ...

Repatha was first approved in 2015 and has since been used by more than 6.7 million patients globally. 3,4 Earlier this year, the U.S. Food and Drug Administration broadened the approved use of ...

(Reuters) -Adding Amgen's cholesterol drug Repatha to standard therapy reduced major cardiovascular events by 25% for at-risk patients who have never had a heart attack or stroke, according to results ...